Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.
IPO Year: 2018
Exchange: NASDAQ
Website: allakos.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/17/2024 | $6.00 → $1.50 | Buy → Hold | Jefferies |
| 1/16/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 12/18/2023 | Mkt Perform → Outperform | William Blair | |
| 12/8/2023 | $9.00 → $6.00 | Buy | Jefferies |
| 9/27/2023 | $11.00 | Mkt Outperform | JMP Securities |
| 5/12/2023 | $6.00 → $9.00 | Hold → Buy | Jefferies |
| 3/7/2023 | $22.00 | Overweight | Piper Sandler |
| 9/12/2022 | $2.00 | Neutral → Underperform | SMBC Nikko |
| 2/16/2022 | $17.00 → $13.00 | Market Perform | SVB Leerink |
| 12/28/2021 | $230.00 → $20.00 | Buy | HC Wainwright & Co. |
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. ("Allakos") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ( "Concentra") will acquire Allakos for $0.33 in cash per share of Allakos common stock ("Allakos Common Stock"). Allakos' Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos' Transaction Committee, has appro
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos Events Reported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025.Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives. Cash Guidance Allakos ended the fourth qua
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (NASDAQ:ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). "While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has decided to discontinue further clinical developme
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2024. Recent Allakos Events Reported safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 trial of subcutaneous (SC) AK006 in healthy volunteers. Bioavailability of subcutaneous AK006 was approximately 77%.Subcutaneous administered AK006 showed an estimated half-life of 12-22 days.Consistent with the IV formulation, skin biopsies taken from sub
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 – SAN CARLOS, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced results from the Phase 1 study of subcutaneous AK006 in healthy volunteers. AK006 is a Siglec-6 monoclonal antibody that selectively inhibits mast cells. Inappropriate activation of mast cells has been identi
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024. Recent Allakos Events Initiated the randomized, double-blind, placebo-controlled Phase 1 trial of intravenous (IV) AK006 in patients with chronic spontaneous urticaria.Completed dosing in the randomized, double-blind, placebo-controlled subcutaneous (SC) AK006 cohort in healthy volunteers.Reported safety, pharmacokinetics (PK), and pharmacodynamic (PD) results f
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile – SAN CARLOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced positive results from the single and multiple ascending Phase 1 study of intravenous (IV) AK006 in healthy volunteers. AK006 is a Siglec-6 monoclonal antibody that selectively inhibits mast cells. Inappropriate activation of mast cells has been id
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006. The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of AK006, and to explore the therapeutic effects of AK006 in patients with CSU using the urticaria activity score (UAS7) at 14 weeks. Top-line results from the trial are expected at year end 2024. Chronic
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and multiple ascending dose (MAD) cohorts of the randomized, double-blind, placebo-controlled Phase 1 trial of Intravenous (IV) AK006 in healthy volunteers.Completed dosing in the randomized, double-blind, placebo-controlled subcutaneous (SC) AK006 cohort in healthy volunteers.Initiated the
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
SC 13G - Allakos Inc. (0001564824) (Subject)
SC 13G/A - Allakos Inc. (0001564824) (Subject)
SC 13G/A - Allakos Inc. (0001564824) (Subject)
SC 13G/A - Allakos Inc. (0001564824) (Subject)
SC 13G/A - Allakos Inc. (0001564824) (Subject)
SC 13G/A - Allakos Inc. (0001564824) (Subject)
SC 13G - Allakos Inc. (0001564824) (Subject)
SC 13D/A - Allakos Inc. (0001564824) (Subject)
SC 13G - Allakos Inc. (0001564824) (Subject)
SC 13G - Allakos Inc. (0001564824) (Subject)
Jefferies downgraded Allakos from Buy to Hold and set a new price target of $1.50 from $6.00 previously
Cantor Fitzgerald downgraded Allakos from Overweight to Neutral
William Blair upgraded Allakos from Mkt Perform to Outperform
Jefferies resumed coverage of Allakos with a rating of Buy and set a new price target of $6.00 from $9.00 previously
JMP Securities initiated coverage of Allakos with a rating of Mkt Outperform and set a new price target of $11.00
Jefferies upgraded Allakos from Hold to Buy and set a new price target of $9.00 from $6.00 previously
Piper Sandler initiated coverage of Allakos with a rating of Overweight and set a new price target of $22.00
SMBC Nikko downgraded Allakos from Neutral to Underperform and set a new price target of $2.00
SVB Leerink reiterated coverage of Allakos with a rating of Market Perform and set a new price target of $13.00 from $17.00 previously
HC Wainwright & Co. reiterated coverage of Allakos with a rating of Buy and set a new price target of $20.00 from $230.00 previously
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (NASDAQ:ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). "While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has decided to discontinue further clinical developme
Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteersa randomized, double-blind, placebo-controlled trial in patients with CSUa subcutaneous AK006 Phase 1 PK and bioavailability trial Management to host conference call and webcast today at 8:00 am E.T. SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 c
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK). "We are disappointed that these trials did not m
SCHEDULE 13G/A - Allakos Inc. (0001564824) (Subject)
SCHEDULE 13D/A - Allakos Inc. (0001564824) (Subject)
EFFECT - Allakos Inc. (0001564824) (Filer)
EFFECT - Allakos Inc. (0001564824) (Filer)
S-8 POS - Allakos Inc. (0001564824) (Filer)
S-8 POS - Allakos Inc. (0001564824) (Filer)
S-8 POS - Allakos Inc. (0001564824) (Filer)
S-8 POS - Allakos Inc. (0001564824) (Filer)
S-8 POS - Allakos Inc. (0001564824) (Filer)
S-8 POS - Allakos Inc. (0001564824) (Filer)
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Ph
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors. "We are very pleased to have such an accomplished physician as Dr. Ladd join our board. Her extensive medical background and expertise will provide valuable insights as we continue to advance lirentelimab and our novel pipeline through clinical trials," said Robert Alexander, Ph.D., the Company's Chief Executive Officer. Dr. L
REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company" or "Allakos") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief Financial Officer. As CFO, Mr. Radford will lead Allakos' finance organization while working with the Company's leadership team to drive its strategic initiatives and operating principles. Mr. Radford has over 25 years of finance and leadership experience at public companies in multiple industries and various stages of growth. Prior to joining Allakos, Mr. Radford served as Senior Vice President of F
REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. “Natalie’s extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide valuable insights as we continue to advance late-stage clinical trials of lirentelimab and begin laying the foundation for its potential commercialization,“ said Robert Alexander, PhD, chief executiv